Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs VANCOUVER, British Columbia and SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to ...